Printer Friendly
The Free Library
23,383,293 articles and books


PACE CLOSES $3.6 MILLION SPECIAL WARRANT FINANCING.

TORONTO--(BUSINESS WIRE)--May 3, 1995--PACE CORPORATION(CANADIAN DEALING NETWORK: PACL ) The Pace Corporation today announced that it has received a receipt for its final prospectus and closed its previously announced private placement financing to raise gross proceeds of $3,615,000. Agent for the financing was Sprott Securities Ltd.

Dr. Jeremy Clapp, President of Pace, said the Company is now adequately financed to permit rapid acceleration of its growth strategies for both its heart attack diagnostic tests and its lead testing products. He said the proceeds of the financing would be used (i) to complete the acquisition of all manufacturing rights for its GPBB-ELISA heart attack diagnostic; (ii) to fund clinical trials for its initial GPBB-ELISA test; (iii) to fund additional heart attack diagnostic R & D for a diverse line of products, both qualitative and quantitative including such markers as Myoglobin, Troponin 1, and Creatine Kinase MB isoenzyme; (iv) to automate manufacturing of its lead testing products; (v) to fund market development of lead testing products; and (vi) working capital.

Dr. Clapp said that clinical trials are expected to commence within a few weeks for the Company's GPBB-ELISA tests and that accelerated development has begun to utilize Pace patented reagents for a series of additional tests including one quantitative stat cardiac diagnostic panel of tests that could provide results in two to three minutes.

The Company also reports that sales of lead test products had increased sharply in recent weeks and that further sales gains could be expected now that market development funds are available.

The Pace Corporation is an international company which develops, manufactures, markets and distributes easy to use, accurate and cost effective medical diagnostic and environmental test kits. Its primary areas of interest are the early differential diagnosis of heart damage, North America's number one killer, and the detection and evaluation of lead poisoning in children, the largest environmental issue in the history of the United States.

Shares of The Pace Corporation are traded on the Canadian Dealing Network (PACL).

CONTACT: The Pace Corporation

Dr. Jeremy Clapp, President & C.E.O., 905/709-1196

or

Kieran and Co. Inc.

Jon W. Kieran or Cathy Hume, Investor Relations,

416/868-1079
COPYRIGHT 1995 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1995, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:May 3, 1995
Words:362
Previous Article:Miller announces first production capability in Central America
Next Article:Laurence Hootnick Resigns from NetManage's Board of Directors.
Topics:



Related Articles
PACE RAISES OVER $3.6 MILLION WITH PLACEMENTS OF SPECIAL WARRANTS.
Torstar Corporation Becomes Strategic Partner and Major Shareholder of JCI Technologies Inc.
Pace Accepts Financing Offer.
Carlin Resources Corp. makes announcement.
Carlin Resources Corp. announces that its previously announced agreement with Cannaccord Capital has been revised.
Intraware Nets $3.3 Million in Financing.
Acusphere Announces $21.5 Million Private Financing.
Diomed Holdings, Inc. Agrees to $10.6 Million Financing; Investors to Purchase $7 Million in Senior Convertible Debt and $3.6 Million of Common Stock.
Diomed Holdings, Inc. Completes $10.6 Million Financing.
Lending enjoys healthy pace.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters